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Although neurological disease has been recognized since antiquity, neurology as a systematic 
clinical discipline is less than 130 years old. Neurological practice has traditionally been 
constrained by the complexity of the human nervous system, which has been slow to yield its 
secrets. Over the last three decades, however, clinical neurology has been transformed in terms 
of both diagnostics and therapeutics and now marches in lockstep with the cutting edge of 
medicine. Efficacious treatments are now available for the majority of neurological diseases, 
including epilepsy, migraine, Guillain-Barre syndrome, Parkinson's disease, multiple sclerosis, 
and ischemic stroke. This neurological revolution has been enabled by advances in neuroimaging 
and through the integrated application of basic research, drug development, biotechnology and 
clinical trial methodology. Neurology in the 21st century is a dynamic specialty offering relief and 
benefit to many patients, and holding the promise for one day conquering neurological disease in 
all its manifestations. 
Introduction  
Neurological diseases are common and often devastating illnesses. As a result, the global burden 
of neurological disease is daunting. Stroke is the leading cause of physical handicap worldwide 
and projected to be the 2nd commonest cause of death after heart disease by 2025.1 Epilepsy 
has a worldwide prevalence of up to 3%, and the lifetime risk of a single seizure approaches 
5%.2 The population prevalence of migraine is 3.5-7% and the lifetime prevalence of any severe 
disabling headache exceeds 30%.3 Parkinson's disease afflicts 1 million people in the United 
States alone and is estimated to affect tens of millions around the world.4 Dementia affects 20 
million people worldwide and, as the population of elderly people increases in both developed 
and developing countries, this burden is expected to nearly double by 2025.5 The collective 
human burden of neurological illness is thus enormous. 
Neurological problems have been recognized since antiquity, but neurology as a systematic 
clinical discipline is less than 130 years old. In 1882, Jean-Martin Charcot became professor of 
neurology at the University of Paris, in recognition of clinical investigation and scholarship 
devoted to neurological signs and symptoms.6 Neurology as an institutionalized medical specialty 
can be said to have been born in Charcot's ward at the Salpetriere Hospital, where the clinical 
neurological examination was developed and neurological diseases subjected for the first time to 
clinico-pathologic study. Neurology has continued to be blessed with eminent and gifted 
physician-scientists through the 19th and 20th centuries, but the practice of neurology has 
traditionally been constrained by the complexity of the human nervous system. 
In the latter half of the 20th century, a number of landmark advances from different areas of 
biomedical science converged to transform the science and practice of medicine in far-reaching 
and fundamental ways. The neurological applications of these advances - including 
developments in imaging technology, molecular biology, drug development and epidemiology - 
have transformed the care of neurological diseases into a rigorous clinical discipline with powerful 
diagnostic tools and an increasingly larger array of therapeutic options. Neurology in the 21st 
century is a robust and dynamic specialty offering relief and benefit to many patients, and holding 
the promise for one day conquering neurological disease in all its manifestations. 
 
Diagnostic Advances  
 
Most of the bedrock tools of diagnostic neurology - lumbar puncture (LP), 
electroencephalography (EEG), electromyography and nerve conduction studies (EMG/NCS), 
and evoked potentials (EP) - have been available for the greater part of the last century.7 The 
true revolution in diagnostic neurology did not come until the 1970s and 80s, when it became 
possible to visualize the brain and spinal cord during life. Contemporary clinicians will find it hard 
to imagine that neurological practice was once conducted without computed tomography (CT) or 
magnetic resonance imaging (MRI), yet prior to the mid-1970s (when CT scanning became 
widely available), the living brain could not be imaged at all and brain structure was assessed 
only indirectly, by studying calcified pineal glands on plain skull X-rays, distorted ventricular 
contours on pneumoencephalography, or abnormal vascular anatomy on invasive cerebral 
angiography.8 The latter two procedures were fraught with great discomfort and risk of 
complications, involving injection of air into the subarachnoid space by lumbar puncture 
(pneumoencephalography) and direct arterial puncture of the carotid artery in the neck 
(angiography). 
 
CT and MRI:  
 
Modern neuroimaging allows visualization of the living brain, spinal cord and associated 
vasculature with great sophistication and detail; as a consequence the practice of neurology has 
been transformed. CT and MRI both permit high-quality anatomic resolution of all pathologic 
processes involving the neuraxis, including infarction, hemorrhage, inflammation, infection, 
neoplasia and congenital.9 Novel MRI sequences have been customized for specific 
abnormalities10, including diffusion-perfusion for ischemia; gradient-recalled echo for early and 
remote hemorrhage; fat-suppression for enhanced visualization in the skull base, neck and spinal 
canal; fluid attenuation inversion recovery (FLAIR) for exquisite detection of parenchymal 
abnormalities; and magnetization transfer contrast for conspicuous visualization of multiple 
sclerosis plaques or metastatic deposits in the brain. 
Vascular imaging has also greatly advanced through CT and particularly MRI. Magnetic 
resonance angiography (MRA) uses no extraneous contrast and identifies stenoses in the 
intracranial and cervical vasculature with sufficient resolution for routine clinical use. Although 
MRA tends to overestimate the degree of stenosis, its clinical value as a screening angiographic 
procedure remains paramount.11 CT angiography requires intravenous iodinated contrast and 
uses a helical scanning technique to reconstruct vascular anatomy, allowing detailed two-
dimensional as well as three-dimensional reconstruction of the carotid system.12 Helical CT also 
enables realistic three-dimensional reconstructions of complex anatomic regions, such as the 
orbit or the skull base, that are becoming indispensable to surgical management. 
 
Functional neuroimaging:  
 
While the standard clinical use of CT and MRI involves structural imaging, functional brain 
imaging promises to mark the dawn of a new era in understanding and diagnosing neurological 
disease. For decades, the only diagnostic tool for functional study of the brain was EEG, in which 
patterned electrical activity from the cortical mantle is recorded by surface electrodes on the 
scalp. Functional neuroimaging technology relies on the ability to measure minute differences in 
regional cerebral blood flow, as in PET (positron emission tomography)13, SPECT (single photon 
emission computed tomography)14 and functional MRI (fMRI).15 A parallel technique is magnetic 
resonance spectroscopy (MRS), in which local concentrations of biological chemicals can be 
measured in vivo and expressed as an imaging signal.16 Magnetoencephalography is another 
functional imaging technique that takes the functional signals of standard EEG and maps them on 
to two-dimensional axial brain anatomy.17 The excitement surrounding functional neuroimaging 
comes from the greater mechanistic understanding of neurological disease that this technology 
has enabled. At present, clinical applications are limited to specialized situations, such as 
identification of seizure foci in patients being considered for epilepsy surgery. With improved 
technology, lowered cost, and advances in research, it is only a matter of time before functional 
neuroimaging pushes back the frontiers of neurology through clinical applications as well. 
 
 
Molecular diagnostics:  
 
As in other clinical fields, textbooks in neurology have also been rewritten with the molecular 
biology revolution that has taken place over the last two decades. The genetic defects underlying 
a vast number of neurological diseases have been discovered, contributing to a refined nosology 
and promising a hitherto unimagined level of mechanistic understanding. The genetic 
abnormalities range from point mutations and deletions to gene duplications and triplet repeat 
expansions - all conveniently assayed through modern DNA diagnostic technology and providing 
100% diagnostic accuracy for several confusing and complex, albeit uncommon, 
neurodegenerative disorders.18 With the success of the Human Genome Project, these 
molecular advances promise not only to make DNA diagnostics commonplace but also to create 
remarkable new research possibilities that will one day hopefully lead to rational therapies for 
many or all of the neurodegenerative and neurogenetic conditions that remain unconquered 
today. 
 
Advances in Therapeutics  
 
Long considered a field dominated by therapeutic nihilism, neurology in the 21st century has 
begun to march in lockstep with the rest of clinical medicine. Although many devastating 
neurodegenerative diseases remain for which no efficacious treatment exists, modern 
neurologists are equipped with sufficient treatment options to make a difference to disease 
manifestation or outcome in most of their patients. 
 
Ischemic stroke  
 
In 1996, the first scientifically proven treatment for acute ischemic stroke appeared in the form of 
the intravenous thrombolytic drug tissue plasminogen activator (tPA). When administered to 
ischemic stroke patients within 3 hours of symptom onset, this drug is associated with a 30% 
greater likelihood of eventually being able to walk unaided, compared to placebo.19 The intra-
arterial agent pro-urokinase has also been studied in a carefully conducted clinical trial and found 
efficacious in improving functional outcome in patients with middle cerebral artery infarction due 
to local arterial thrombus.20 The possibility of limiting acute stroke damage by neuroprotective 
drugs - agents that block the cellular and biochemical effects of ischemia - has also emerged in 
recent years. Although this strategy remains unproven in human clinical trials, the large amount of 
exciting animal model data and sound theoretical foundations of this approach, indicate that it is 
almost certainly a treatment of the future.21 The availability of urgent interventions for acute 
ischemic stroke has changed the very landscape of stroke care, which comprises the bulk of 
acute emergency neurology. 
Rational and efficacious secondary prevention strategies are now also available for every 
ischemic stroke patient. Patients with ipsilateral 70-99% stenosis of the internal carotid artery can 
achieve significant stroke risk reduction with carotid endarterectomy.22 In selected patients, a 
less invasive option is carotid angioplasty with stenting, whose precise safety and efficacy is 
currently under investigation.23 Patients with atrial fibrillation, prosthetic heart valves or 
hypokinetic left ventricles are at particularly increased risk for cerebral thromboembolism and can 
be protected with oral warfarin titrated to an INR of 2.0 - 3.0.24 All other ischemic stroke patients 
are able to reduce their recurrence risk with anti-platelet therapy. Currently the most efficacious 
combination is aspirin and extended-release dipyridamole; the combination of aspirin and 
clopidogrel may be more effective and is under investigation.25 
Epilepsy. With judicious use of anticonvulsants, the great majority (>80%) of patients with 
epilepsy can be made seizure-free or almost seizure-free and are able to lead normal and 
productive lives.26 Although phenobarbital has been available since 1912 and phenytoin has 
been available since 1938, as recently as the 1960s satisfactory seizure control was possible in 
less than two-thirds of epilepsy patients. Both phenobarbital and phenytoin are associated with 
potentially limiting side-effects. Carbamazepine is structurally related to tricyclic antidepressants 
and first appeared in the 1950s as a treatment for trigeminal neuralgia; its anticonvulsant 
properties were soon recognized. Valproic acid, developed in the 1970s and appearing on the 
market in 1978, was another important addition and remains one of the most efficacious 
anticonvulsants for primary generalized seizures. Beginning in the 1990s, however, a very wide 
selection of new anticonvulsants became available, including gabapentin, tiagabine, 
levetiracetam, oxcarbazepine, lamotrigine, topiramate and vigabatrin.26 This vast addition to the 
neurologist's therapeutic repertoire represents the combined triumph of industrial drug 
development and clinical trial methodology. 
While the classical anticonvulsants - phenytoin, carbamazepine and valproic acid - remain the 
most commonly prescribed anti-epileptic drugs, clinical indications for the newer agents are 
increasingly being defined. Most of these agents are used as adjunctive therapy and are effective 
in significantly reducing seizure frequency in patients only partially controlled with the classical 
agents. Because of almost nonexistent cognitive side-effects and proven efficacy against partial 
as well as generalized seizures, lamotrigine is emerging as the drug of first choice in the first-line 
management of uncomplicated epilepsy.27 Gabapentin, though a relatively weak anticonvulsant, 
has no major side-effects and no significant drug interactions, making it an excellent choice for 
managing seizures in medically complex patients, such as critically ill patients with multi-organ 
dysfunction.28 Epilepsy in the 21st century is completely compatible not only with a normal and 
productive life, but also with pregnancy and motherhood. Although all anticonvulsants are 
potentially teratogenic, lamotrigine has the safest record of use during pregnancy. Since pre-
conception seizure control predicts seizure risk during pregnancy, an epileptic woman well 
controlled on lamotrigine can expect nearly the same pregnancy outcomes as healthy women.29 
An important caveat is that the available anti-epileptic agents represent symptomatic control only 
- they are effective seizure suppressants but have no effect on epileptogenesis, the pathologic 
process(es) responsible for seizure generation in the first place. With ongoing exponential 
advances in neuropharmacology and in our understanding of synaptic plasticity and associated 
phenomena, there is every reason to hope that the next generation of anti-epileptic agents will be 
able to modulate epileptogenesis as well, rendering epilepsy curable. 
 
Parkinson's disease  
 
The use of dopamine supplementation in the form of oral levodopa for the control of Parkinsonian 
symptoms represented a revolutionary therapeutic advance in neurology, and one of the most 
dramatic treatment advances in all of clinical medicine. First discovered in 1967, the efficacy of 
levodopa in ameliorating the parkinsonian features of rigidity, bradykinesia and tremor remains 
unsurpassed today, making it the cornerstone of Parkinson's disease management.30 The drug 
is not a panacea, however, and limiting side-effects (most notably motor fluctuations such as on-
off periods and dyskinesias) develop in nearly all patients after a variable period of use. 
Strategies for reducing the risk of developing dyskinesias - such as delayed initiation of levodopa 
or the use of dopamine agonists - have traditionally failed. In recent years, however, two new 
selective dopamine agonists - ropinirole and pramipexole - have become available whose initial 
use in Parkinson's disease significantly delays the onset of dyskinesias, improving and prolonging 
quality of life.31 The concurrent use of catechol-O-methyltransferase (COMT) inhibitors reduces 
time spent in the off-period, presumably by stabilizing dopamine availability at the remaining 
nigrostriatal nerve terminals.32 Although mortality in Parkinson's disease remains unchanged and 
several unmet symptomatic needs also persist, these therapeutic advances doubtless offer the 
chance of enhanced quality of life to many parkinsonian patients. 
 
Multiple sclerosis  
 
The classic nihilistic image of multiple sclerosis (MS) as an untreatable neurodegenerative 
disorder has been radically altered in the face of disease-modifying immunomodulatory therapy 
made available in the 1990s through intensive basic research, clinical experimentation and 
cutting-edge biotechnology. The use of beta-interferon33 or glatiramer acetate34 results in an 
approximately 30% lower annual relapse rate in multiple sclerosis patients compared to placebo. 
The benefit is also detectable in terms of reduced plaque burden on MRI as well as better clinical 
scores on scales of functional performance such as the Extended Disability Status Scale. The 
use of beta-interferon after an initial attack of central demyelination (optic neuritis, incomplete 
transverse myelitis, or a brainstem or cerebellar syndrome) also reduces the subsequent 
likelihood of developing MS.35 Despite these advances, however, the effectiveness of treatment 
for MS remains limited and efforts to develop better agents remain intense. Mitoxantrone (an 
antineoplastic agent)36 and natalizumab (a monoclonal antibody directed against the adhesion 




One of the commonest neurological afflictions, migraine attacks are capable of producing 
excruciating, incapacitating craniofacial pain. Traditionally, the management of acute migraine 
attacks has relied on nonsteroidal analgesics, which often provide only partial relief and may 
require combination with barbiturate or opiate agents that are likely to produce addiction and 
habituation. With the help of new insights into the pathophysiology of migraine, abortive therapy 
for acute migraine attacks has been revolutionized. The 'triptans', a group of serotonin receptor 5-
HT 1B/1D agonists, are capable of producing quick and dramatic relief in 70-90% of migraine 
attacks.38 Following the availability of sumatriptan in 1991, a wide selection of these agents has 
been developed, including rizatriptan, zolmitriptan, naratriptan, almotriptan, frovatriptan and 
eletriptan. Because over 70% of migraine attacks are associated with nausea and vomiting, many 
of these agents are available in non-oral formulations, including subcutaneous injection, 
intranasal spray and rectal suppositories.39 
 
Alzheimer's Disease  
 
Dementia, perhaps the most dehumanizing of the neurological illnesses, is the quintessential 
neurodegenerative disease. Alzheimer's disease (AD) - the commonest form of dementia - was 
recognized as a distinct pathologic entity in 1907, but mechanistic insights into the condition did 
not emerge until the 1980s. One of the best characterized abnormalities in the brains of AD 
patients is a cholinergic deficit in the cerebral cortex resulting from degeneration of the nucleus 
basalis of Meynert in the basal forebrain, which represents the major source of cortical cholinergic 
projections.40 Although by no means a revolutionary or dramatic treatment, attempts to replace 
the cholinergic deficit in AD patients does result in measurable improvement in the rate of 
cognitive decline compared to placebo, as assessed by validated scales of cognitive performance 
and activities of daily living.41 The medications that are effective in this role - tacrine, 
rivastigmine, donepezil and galantamine - all act by inhibiting acetylcholinesterase to enhance 
cholinergic neurotransmission. There is great expectation that insights into the other well 
recognized abnormalities in AD, including deposition of beta-amyloid in the brain and the 
association with apolipoprotein E4, will yield therapeutic dividends as well. 
 
Guillain-Barre Syndrome  
 
With the global decline in poliomyelitis, Guillain-Barre syndrome is now the leading cause of 
acute flaccid paralysis worldwide. The disorder is uncommon though not rare, and has been 
associated with a small but significant mortality as well as risk of chronic disability.42 Although 
questions about etiology, prognosis and outcome predictors in GBS remain incompletely 
answered, the immunomodulatory treatments of plasma exchange (PE) and intravenous 
immunoglobulin (IVIg) have proven efficacy in clinical trials.43 Compared to supportive care 
alone, GBS patients receiving either PE or IVIg are at least 50% less likely to be on a ventilator 
after 4 weeks, and up to 25% more likely to have full motor strength recovery after 1 year.43 GBS 
is being increasingly recognized as an autoimmune attack on peripheral nerves, possibly 
triggered by antecedent infection. Epidemiological insights, such as the strong association of 
Campylobacter jejuni infection with the axonal form of GBS, may hold the key to understanding 
the ultimate immunological basis of GBS and creating opportunities for more efficacious 
therapy.44  
 The Future  
 
Modern neurology is a transformed discipline. As recently as three decades ago, neurological 
practice was based on a small repertoire of poorly tolerated drugs and, without the ability to see 
the brain in vivo, largely on blind diagnostics. In remarkable contrast, neurologists in the 21st 
century are at the center of a dynamic, vibrant clinical specialty with high diagnostic certainty and 
an ever-expanding choice of efficacious therapeutic options.  
The future holds great promise for further landmark achievements in neuroimaging as well as in 
neurological therapeutics. There is no theoretical upper limit to the anatomic resolution possible 
through MRI, so an ever greater degree of detail can be expected with advancing magnetic 
resonance technology. Functional neuroimaging, while it continues to unlock the great secrets of 
brain function, can also be expected to enter routine clinical use for indications involving epilepsy, 
tumors and possibly dementias. With fundamental discoveries in genomics, proteomics and 
cellular pathophysiology, the mechanistic bases of many untreatable neurodegenerative 
conditions - entities like motor neuron disease, Huntington's disease, advanced dementias, 
advanced Parkinson's disease and crippling neurogenetic disorders - will become known, 
creating hope for effective treatment. Even in the absence of such mechanistic leads, powerful 
biotechnology tools such as gene therapy and monoclonal antibody technology can be expected 
to keep expanding the neurologist's therapeutic armamentarium. 
Undoubtedly, the changed character of neurological practice will bring about new perceptions 
about the field among patients, prospective trainees, clinicians from other specialties, and the 
public at large. The ultimate reward is what these advances have already enabled, and will 
continue to enable, in terms of better care of patients with neurological illnesses. For neurology 
and for the patients it serves, the future is bright. 
 
Comments  
The analysis shows that Jinnah Postgraduate Medical Centre facilities are mostly being utilized 
for investigation purposes. Basic drugs (analgesics, antacids and multivitamins) are being 
provided to the patients while specific drugs like antibiotics, anti ulcers oral hypoglycemics and 
seizure controlling drugs etc are not provided and the patients have to purchase them on their 
own. 
In order to improve the health delivery system, efforts should be directed to shorten the time 
spent by the patient in the OPD's along with reduction in the number of visits made by the 
patients. 
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